AstraZeneca Names Roche’s Pascal Soriot as CEO

AstraZeneca Plc named Pascal Soriot, Roche Holding AG’s head of pharmaceuticals, as chief executive officer to revive sales and product development as the U.K. company faces one of the industry’s biggest patent expirations.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.